Ameriprise Financial Inc Revance Therapeutics, Inc. Transaction History

Ameriprise Financial Inc

  • $381 Billion
  • Q3 2024

A detailed history of Ameriprise Financial Inc transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Ameriprise Financial Inc holds 15,380 shares of RVNC stock, worth $39,526. This represents 0.0% of its overall portfolio holdings.

Number of Shares
15,380
Previous 167,948 90.84%
Holding current value
$39,526
Previous $431,000 90.95%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
SELL
$2.57 - $2.57 $392,099 - $392,099
-152,568 Reduced 90.84%
15,380 $39,000
Q2 2024

Aug 14, 2024
SELL
$2.34 - $4.73 $4,593 - $9,284
-1,963 Reduced 1.16%
167,948 $431,000
Q1 2024

May 15, 2024
SELL
$4.65 - $9.31 $38,092 - $76,267
-8,192 Reduced 4.6%
169,911 $835,000
Q4 2023

Feb 14, 2024
BUY
$5.81 - $11.2 $303,770 - $585,580
52,284 Added 41.55%
178,103 $1.57 Million
Q3 2023

Nov 14, 2023
SELL
$11.47 - $25.07 $1 Million - $2.19 Million
-87,297 Reduced 40.96%
125,819 $1.44 Million
Q2 2023

Aug 14, 2023
SELL
$24.7 - $37.61 $1.68 Million - $2.55 Million
-67,866 Reduced 24.15%
213,116 $5.39 Million
Q1 2023

May 15, 2023
BUY
$18.36 - $35.27 $857,650 - $1.65 Million
46,713 Added 19.94%
280,982 $9.05 Million
Q4 2022

Feb 14, 2023
BUY
$18.32 - $30.66 $1.21 Million - $2.03 Million
66,207 Added 39.39%
234,269 $4.32 Million
Q3 2022

Nov 14, 2022
BUY
$14.33 - $28.47 $355,341 - $705,970
24,797 Added 17.31%
168,062 $4.54 Million
Q2 2022

Aug 15, 2022
BUY
$11.52 - $20.4 $91,445 - $161,935
7,938 Added 5.87%
143,265 $1.98 Million
Q1 2022

May 16, 2022
BUY
$12.36 - $20.31 $171,655 - $282,065
13,888 Added 11.44%
135,327 $2.64 Million
Q4 2021

Feb 14, 2022
SELL
$12.46 - $27.87 $554,856 - $1.24 Million
-44,531 Reduced 26.83%
121,439 $1.98 Million
Q3 2021

Nov 15, 2021
BUY
$25.78 - $33.21 $283 - $365
11 Added 0.01%
165,970 $4.62 Million
Q2 2021

Aug 16, 2021
BUY
$26.8 - $31.84 $429,952 - $510,809
16,043 Added 10.7%
165,959 $4.92 Million
Q1 2021

May 17, 2021
SELL
$24.03 - $29.97 $237,993 - $296,822
-9,904 Reduced 6.2%
149,916 $4.19 Million
Q4 2020

Feb 12, 2021
BUY
$23.41 - $28.34 $640,240 - $775,070
27,349 Added 20.65%
159,820 $4.53 Million
Q3 2020

Nov 16, 2020
SELL
$23.23 - $34.3 $351,423 - $518,890
-15,128 Reduced 10.25%
132,471 $3.33 Million
Q2 2020

Aug 14, 2020
SELL
$12.6 - $26.55 $607,395 - $1.28 Million
-48,206 Reduced 24.62%
147,599 $3.61 Million
Q1 2020

May 15, 2020
SELL
$12.46 - $27.81 $268,724 - $599,778
-21,567 Reduced 9.92%
195,805 $2.9 Million
Q4 2019

Feb 14, 2020
BUY
$11.66 - $20.15 $820,910 - $1.42 Million
70,404 Added 47.9%
217,372 $3.55 Million
Q3 2019

Nov 14, 2019
BUY
$10.22 - $14.5 $293,753 - $416,773
28,743 Added 24.31%
146,968 $1.91 Million
Q2 2019

Aug 14, 2019
SELL
$10.67 - $15.49 $188,613 - $273,816
-17,677 Reduced 13.01%
118,225 $1.53 Million
Q1 2019

May 15, 2019
BUY
$15.4 - $20.39 $1.62 Million - $2.15 Million
105,265 Added 343.59%
135,902 $2.14 Million
Q4 2018

Feb 14, 2019
BUY
$18.06 - $24.96 $20,281 - $28,030
1,123 Added 3.8%
30,637 $617,000
Q3 2018

Nov 14, 2018
BUY
$23.55 - $30.1 $56,567 - $72,300
2,402 Added 8.86%
29,514 $733,000
Q2 2018

Aug 14, 2018
SELL
$27.45 - $33.35 $785,207 - $953,976
-28,605 Reduced 51.34%
27,112 $744,000
Q1 2018

May 15, 2018
SELL
$29.15 - $37.4 $259,347 - $332,747
-8,897 Reduced 13.77%
55,717 $1.72 Million
Q4 2017

Feb 12, 2018
BUY
$24.55 - $36.3 $1.02 Million - $1.51 Million
41,630 Added 181.13%
64,614 $2.31 Million
Q3 2017

Nov 07, 2017
BUY
$22.55 - $28.1 $518,289 - $645,850
22,984
22,984 $634,000

Others Institutions Holding RVNC

# of Institutions
234
Shares Held
82.8M
Call Options Held
680K
Put Options Held
896K
View Full List

About Revance Therapeutics, Inc.

RVNC Quotes by TradingView
  • Ticker RVNC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 82,305,696
  • Market Cap $212M
  • Description
  • Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...
More about RVNC
Track This Portfolio

Track Ameriprise Financial Inc Portfolio

Follow Ameriprise Financial Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ameriprise Financial Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ameriprise Financial Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email